Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Address

FIFTH FLOOR, WATERLOO EXCHANGE
DUBLIN, L2 4

Founded

2005

Number of Employees

2,800

Website

http://www.jazzpharmaceuticals.com

Buyback

Buyback Data 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
$ Amount Purchased
($ in 000s)		 $29,974 $21,301 $259,818 $56,425 $77,015 $191,116 $146,535 - $54 $269,756 $161,423 $121,342
Average Price $131.89 $172.43 $125.65 $141.73 $154.03 $131.48 $121.98 - $160.70 $126.64 $110.75 $126.93
# Shares Purchased 227,267 123,539 2,067,825 398,114 500,004 1,453,621 1,201,300 - 338 2,130,047 1,457,544 955,960
Buyback Performance 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
Total Return to Date -18.1% -37.4% -14.0% -23.8% -29.9% -17.9% -11.5% - -32.8% -14.7% -2.5% -14.9%
S&P 500 Return to Date 181.9% 173.0% 168.6% 129.7% 104.9% 93.1% 74.8% - 37.3% 31.3% 7.4% 100.2%
Excess Total Return -200.0% -210.3% -182.6% -153.5% -134.7% -111.0% -86.3% - -70.1% -46.1% -9.9% -115.1%
Quartile Rank
Percentile Rank 25% 20% 26% 27% 21% 26% 23% - 19% 22% 36% 31%
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)

People also followed
BIOMARIN PHARMACEUTICAL INC
ARGENX SE
ALNYLAM PHARMACEUTICALS, INC.
ALNYLAM PHARMACEUTICALS, INC.

Regulus Therapeutics Inc.